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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) encompasses a fibrous-like tumor-associated stroma, 
desmoplasia, produced by cancer-associated fibroblasts (CAFs). As desmoplasia plays dual pro- and anti-
tumor roles, efforts are being made to induce its anti-tumor functions for therapeutic gain. We conducted 
biomechanical manipulations, using variations of pathological and physiological substrates in vitro, to 
culture patient-harvested CAFs and generate desmoplastic CAF-derived extracellular matrices (CDMs) 
that can restrict PDAC growth and invasion. We posited that extrinsic modulation of the environment, via 
substrate rigidity, influences CAF’s cell-intrinsic forces affecting CDM production. Substrates used were 
polyacrylamide gels of physiological (~1.5 kPa) or pathological (~7.5 kPa) stiffnesses. Results showed 
that physiological substrates influenced CAFs to generate CDMs similar to normal/control fibroblasts. 
We found CDMs to be softer than the corresponding underlying substrates, and CDM fiber anisotropy 
(i.e., alignment) to be biphasic and informed via substrate-imparted morphological CAF aspect ratios. 
Further, the biphasic nature of CDM fiber anisotropy was mathematically modeled and postulated a 
correlation between CAF aspect ratios and CDM alignment; regulated by extrinsic and intrinsic forces to 
conserve minimal free energy. Biomechanical manipulation of CDMs, generated on physiological 
stiffness substrates, lead to reduction in nuclear translocation of pERK1/2 in KRAS-driven PDAC. 
Specifically, ERK2 was essential for CDM-regulated tumor cell invasion. In vitro findings were validated 
in vivo, where nuclear pERK1/2 was found significantly higher in human PDAC samples compared to 
matching normal pancreata. The study suggests that altering underlying substrates enables CAFs to 
remodel CDMs and restricts KRAS-driven PDAC invasion in an ERK2 dependent manner. 
 
Significance 
The pancreatic ductal adenocarcinoma (PDAC) 5-year survival rate is ~8%; by 2020, PDAC will become 
the second most lethal cancer in the US. PDAC includes a fibrous-like stroma, desmoplasia, 
encompassing most of the tumor mass, which is produced by cancer-associated fibroblasts (CAFs) and 
their cell-derived extracellular matrices (CDMs). Since elimination of CAFs has proven to be detrimental 
to patients, CDM reprogramming, as opposed to desmoplasia ablation, is therapeutically desirable. Data 
from this study suggest that the architecture of CDMs, and not necessarily matrix stiffness, could be 
manipulated to render a tumor-suppressive microenvironment. Hence, treatments that could reprogram 
desmoplasia to become tumor-suppressive/restrictive or that could target tumoral ERK2 might provide 
new means for treating PDAC patients in the future.   




Fibroblastic stromal extracellular matrices (ECMs) modulate essential cellular behaviors such as 
differentiation, migration, proliferation, and survival [1]. In epithelial cancers such as pancreatic ductal 
adenocarcinoma (PDAC), loss of the homeostatic equilibrium of normal stroma induces mechanical and 
biochemical changes, resulting in dynamic activation of fibroblastic pancreatic stellate cells (PSC). In 
turn, the resultant activated cancer-associated fibroblasts (CAFs) remodel and deposit CAF-derived 
ECMs (CDMs), generating a dynamically altered fibrotic tumor microenvironment known as desmoplasia 
[2, 3]. Biomechanical characteristics of desmoplasia, such as ECM fiber anisotropy (i.e., parallel 
organized CDM fibers), have been correlated with poor cancer survival in numerous epithelial cancers, 
including PDAC [4-6], yet the mechanisms by which desmoplastic stroma promotes tumor progression 
remain unclear.  
Along with stromal alterations, over 90% of all PDACs encompass KRAS mutations [7-9], which 
are evident during early phases of PDAC manifestation [10] and essential for both tumor initiation and 
progression [11, 12]. Despite the high frequency of activating KRAS mutations (e.g., KRASG12D), PDAC 
development and progression depends on chronic KRAS stimulation, including of the mutant allele, by 
the tumor-associated desmoplastic stroma [13-15]. Notwithstanding the recognition of the key role of 
KRAS in the development/progression of PDAC, therapies targeting KRAS signaling have failed to show 
clinical efficacy [16, 17]. As an alternative approach, targeting the stromal reciprocity that maintains 
KRAS active [13] may assist in treating this disease. 
While CAFs are responsible for producing and remodeling CDMs and maintaining many of the 
tumorigenic aspects of desmoplasia [18-20], ablation of CAFs is detrimental to patients [21]. Therefore, 
CAF reprogramming, i.e. harnessing the innate, tumor-restrictive properties of the “normal” 
microenvironment, as opposed to stromal ablation, is an attractive therapeutic approach [22-26]. Many 
studies have suggested that pancreatic tumor stiffness is significantly greater than the physiological 
pancreas [27]. Tissue stiffness is a major factor that regulates naïve-to-CAF activation as well as CAFs’ 
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ability to remodel desmoplastic ECMs [28]. The contractility of adherent cells (e.g., myofibroblastic 
CAFs), in concert with the extracellular physical properties of the substrate, constitute, respectively, the 
intrinsic and extrinsic forces needed to regulate tissue architecture (e.g., ECM isotropy) [25, 28-31]. 
Nonetheless, the biomechanical mechanisms that enable a stromal ECM production with tumor-
restrictive, as opposed to tumor-permissive, capabilities remain unclear. 
This study tests the hypothesis that manipulations altering ECM architecture or intracellular CAF 
myofibroblastic contractility could result in a “normalized” tumor-restrictive microenvironment. In 
testing our hypothesis, we first investigated whether modulating substrate rigidity affects the ability of 
CAFs to adjust CDM fiber anisotropy and/or rigidity. We further questioned whether CDMs could be 
modified to restrict, rather than promote, KRAS-driven tumorigenicity of PDAC cells. While our 
previous studies presented a mathematical model to explain the correlation between stiffness, cell 
polarization and matrix alignment [32], we now modified this model to explain how physiological 
substrate stiffness triggers isotropic normalization of CDMs. Our results suggest that physiological 
stiffness can affect CAFs to produce CDMs that restrict tumor cell growth and invasion by preventing 
nuclear localization of activated extracellular signal-regulated kinase (ERK) in an ERK2 dependent 
manner. 
Results 
To assess stiffness-modulated CAF morphology, patient-harvested CAFs [33] were cultured on 
collagen-I conjugated polyacrylamide gels of pancreatic physiological (physio-gel; ~1.5 kPa) or 
pathological (patho-gel; ~7 kPa) stiffnesses [27] using glass coverslips as a rigid-substrate control. As 
seen in Figure 1, the cell aspect ratio (i.e., length over width) of CAFs indicated a biphasic distribution, 
with a peak of about 3 times length over width for CAFs cultured on patho-gels, compared to CAF aspect 
ratios of 1.8 and 2.3, respectively, measured on physio-gels and glass coverslips. A similar, but discrete, 
trend was observed when control (i.e., inactive) fibroblasts were used (Supplemental Figure 1A). These 
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results indicated that physiologically soft substrates can limit the aspect ratio of CAFs rendering round, as 
opposed to spindled, morphologies. 
 
Figure 1: Changes in substrate stiffness dictate a biphasic distribution of CAF aspect ratios. Images correspond to epi-
fluorescent microscopy acquired CAFs labeled to depict cell morphology (CalceinAM; green) and nuclei (blue) cultured onto 
physio (~1.5 kPa), patho (~7 kPa) gels or glass coverslips. Graph includes measured CAF aspect ratios (length/breadth) 
calculated using MetaMorph software (below). Data is presented as median ± interquartile range. Asterisks correspond to * 
p<0.05 and ** p<0.01, compared to ratios attained by CAFs onto patho-gels.  
We next questioned if the patterns of fiber alignment in CDMs correlate with the observed 
substrate stiffness-induced biphasic cell morphologies. For this, CAFs were cultured at high density on 
physio-gels, patho-gels or glass coverslips and allowed to produce CDMs. To assess the level of 
anisotropy at the cell-substrate interface, CDM fiber alignment was calculated from reconstructed 
quantitative confocal scanning images using the OrientationJ plugin for ImageJ software. For each 
condition, fiber alignment was calculated as the percentage of fibers oriented within 15 degrees from the 
measured orientation angle mode [33, 34]. Results revealed a biphasic fiber anisotropy: on physio-gels 
only ~30% of the fibers were aligned, while patho-gels induced a greater alignment (> 60%), yielding 
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considerable fiber anisotropy. On glass coverslips, only ~40% of the fibers were aligned (measuring at the 
cell-substrate interphase). These data suggest a positive correlation between the underlying surface-
instructed cell morphology and CDM fiber anisotropy (Figure 2A). A similar trend, albeit to a lesser 
degree, was observed using control fibroblasts (Supplemental Figure 1B). 
 
Figure 2: Changes in substrate stiffness dictate a biphasic distribution of CDM alignment and a linear increase in CDM 
stiffness. (A) Reconstituted maximum projections of confocal images obtained from gel or glass to CDM interphases, as 
Malik et al:     “Substrate softening normalizes stromal matrices” 
 7 
indicated. Fibronectin is shown in green merged with CAF cell nuclei (blue; top images) or as a monochromatic image (white; 
bottom images) containing a colored insert, indicative of fiber angle distributions, obtained with the ‘OrientationJ’ plugin of 
Image-J software and that was normalized using the hue function of Photoshop to show the cyan color as indication of fibers 
oriented on the mode measured angles. Color gradient bar on the right provides a color palate indicative of angle distributions. 
Graph includes the measured percentages of fibers distributed at 15˚ from the mode angle. Note that the CDM fiber anisotropy 
is at peak levels when CDMs are produced onto patho-gels. (B) Indentation moduli of decellularized CDMs produced onto the 
indicated substrates. Results are presented as mean ± standard deviation. Asterisks denote the following significance compared 
to measurements obtained using the patho-gel condition: * p<0.05, ** p<0.01, *** p<0.005 and **** p<0.001.  
Interestingly, either on physio- or patho-gels, CAFs required only 3-5 days of culture to generate 
homogenous CDMs of >15 microns in thickness. This is less than half of the 8 days required to obtain 
CDMs on glass coverslips [33-35] with a CDM thickness of > 5 microns and an overall combined fiber 
anisotropy of > 55% (Supplemental Figure 2A). Similar results were obtained using additional patient-
harvested CAFs (Supplemental Figure 2B). Taken together, our results suggest that both the intrinsic 
mechano-chemical coupling parameter of cells (i.e., CAFs and, to a lesser extent, in control fibroblasts) 
and the extrinsic effects imparted by the underlying substrate stiffness may modulate the level of CDM 
anisotropy. 
Using atomic force microscopy (AFM) to gauge CDM vs. underlying gel stiffnesses, we first 
confirmed the indentation moduli of the engineered gels. As designed, gels exhibited the appropriate 
physiological and pathological stiffnesses of ~1.5 kPa and ~7 kPa, respectively. Interestingly, CDMs 
presented with numbers of magnitude lower stiffnesses (i.e., indentation moduli), compared to the 
corresponding underlying substrates (Figures 2B and Supplemental 3). Nonetheless, when control 
fibroblasts as opposed to CAFs were used to produce cell-derived ECMs, the indentation moduli were ~1 
kPa in all cases, regardless of substrate stiffness (Supplemental Figure 3). These results suggest that, in 
terms of the indentation moduli, the extrinsic effects imparted by the various substrates mostly affect 
matrices produced by CAFs. Furthermore, the substrate-directed CDM stiffness is independent of both 
fiber anisotropy and cell-aspect ratios. Altogether these results suggest that, by using substrates of 
pancreatic physiological stiffness (i.e., physio-gels of ~1.5 kPa), it is possible to modulate the CDMs 
production, with regards to both fiber alignment and stiffness, to phenotypically resemble normal ECMs.  
In order to explain the biphasic underlying stiffness-dependence of both CAF cell aspect ratios 
and corresponding CDM fiber alignments, we applied and modified an existing mechanochemical 
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mathematical “contractile cell model” that was previously used to explain the correlation between 
substrate stiffness and cell polarization [32]. This model described how cells assume energy-favorable 
morphologies by "sensing” underlying surfaces of variating stiffness via intrinsic chemical energy, arising 
from myosin motors, and extrinsic mechanical energy imparted by substrate stiffness. Here we used a 
similar approach to include the cell-substrate interfacial energy that is directly associated with cell shape 
to determine the aspect ratios needed for cells to attain a given shape by minimizing their total free 
energy. In line with our experimental results, this modified model predicted a biphasic distribution of cell 
aspect ratios as a function of increase in substrate stiffnesses. Figure 3A depicts a theoretical cell that is 
cultured on a surface (blue), where the cell’s aspect ratio (𝑓𝑓) is defined as 𝑓𝑓 = 𝑎𝑎/𝑐𝑐 and in which (𝑎𝑎) is 
the cell’s length and (𝑐𝑐) is its breadth (i.e., with). The accompanying graph depicts the hypothetical 
biphasic changes in cell-aspect ratios predicting CAF shape changes with a maximum aspect ratio found 
at a stiffness that is above the physiological stiffness of the normal pancreas. These theoretical 
calculations predict and validate the experimental observations suggesting a) that, to minimize their total 
free energy, CAFs can dynamically alter their acquired aspect ratios in response to changes in the 
stiffness of their underlying substrates, and b) that these alterations involve both intrinsic/chemical and 
extrinsic/mechanical energies.  
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Figure 3: Biphasic CDM alignment is explained in a minimum free energy model informed by substrate stiffness induced CAF 
aspect ratio. (A) Depiction of the mathematical model conducted to explain the experimentally observed biphasic distribution 
in CAF aspect ratios. (A; left) Schematic representation of a cell (green) spread onto a 2D substrate (blue) used to calculate 
interface energy contribution to total energy. Both cell-substrate interface (red) and free cell surface (gold) are modeled as 
isotropic surfaces with surface energy γ_CM and γ_C (γ_C>γ_CM), respectively. (A; right) The minimum shape energies show 
biphasic response to changes in substrate modulus. K is the effective passive stiffness of the theoretical cellular actin network. 
(B) Depiction of mathematical model designed to explain the observed biphasic distribution in CDMs produced onto surfaces of 
increased stiffnesses, based on the observed/measured CAF aspect ratios. (B; left) Schematic depiction of the model suggesting 
that fiber alignment induced by single cell contraction: Light red area shows the spread of ECM fibers that are affected by a 
single cell, shown in the center. Red cones indicate the predicted local fiber orientations based on the center cell’s aspect ratio. 
(B; right) Graph presenting the predicted CDM fiber alignment expected when informed via the measured CAF aspect ratios 
obtained in Figure 1.  Please refer to Supplemental Table for additional data. 
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We next simulated the active crosstalk between CAFs and the underlying substrate to predict the 
effects of cell contraction on the initial fiber alignment. This simulation was informed by the measured 
cell aspect ratios and conducted by integrating a previously published model for fibrous ECM alignment 
[36] and the above depicted contractile cell models. Figure 3B shows that cell contraction prompts fiber 
alignment in a relative large region (gray), which is approximately 300 times that of the area of a cell. The 
red cones in Figure 3B indicate the predicted fiber orientation based on the cells’ measured aspect ratio. 
Both model predictions and experimental results show that cells become elongated when cultured on 
surfaces of intermediate stiffness, indicating that contraction is mostly uniaxial when the cells are cultured 
on the patho-gels, with CAFs (as opposed to control fibroblasts) exhibiting the highest aspect ratios 
(Figures 1, 2 and Supplemental 1). These results suggest that the observed biphasic aspect ratios, 
informed by the extrinsic stiffness of underlying substrates combined with the intrinsic contractility (i.e., 
chemical energy) of CAFs, dictate the observed biphasic anisotropy of CDMs via maintenance of low free 
energy. 
 Our studies, as well as studies by other groups, have demonstrated that, while CDMs (i.e., 
produced by CAFs) are tumor-permissive, e.g., by supporting cancer cell growth and invasion, ECMs 
derived from normal fibroblasts are tumor-restrictive, e.g., regulate transcription, limit cell motility and 
metastatic invasion as well as alter the manner in which tumor cells transmit integrin-dependent 
biochemical signals [37-40]. Hence, we asked whether CDMs produced by CAFs growing on physio-
gels, but not on patho-gels, could functionally restrict tumorigenic cell behaviors. For this, CDMs [34] 
produced onto physio- vs. patho-gels were decellularized and used as substrates on which we cultured 
transformed human pancreatic ductal epithelial cells (i.e., cells that were immortalized via human 
telomerase reverse transcriptase (hTERT) overexpression and transformed with oncogenic KRASG12D, 
concomitant with inactivation of tumor suppressors Rb and p53 [41]). CDM produced onto physio-gels 
limited cell proliferation, assessed by nuclear detection of Ki67 levels in these cells, by ~2 fold compared 
to levels attained on CDMs produced on patho-gels (Figure 4A). Used as controls, isogenic immortalized 
(e.g., hTERT only) benign human pancreatic epithelial cells presented with similar proliferative trends, 
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albeit to a lesser extent (Supplemental Figure 4A). When both cell types were tested using CDMs made 
on coverslips and compared to matrices made onto gels, proliferation levels correlated with measured 
anisotropic fiber levels, yet the benign cells presented with reduced levels compared to transformed 
(KRAS-driven tumorigenic/invasive) cells (Supplemental Figure 4A). Bare gels (i.e., lacking CDMs) of 
pathological stiffness induced Ki67 incorporation/proliferation to levels akin to the ones observed on both 
cell types on glass, while physiological bare gels significantly restricted Ki67 incorporation in all cases 
(Supplemental Figure 4A).  
Since anisotropic ECMs have also been shown to promote tumor cell invasion in vitro and in vivo 
[38-40, 42], we tested if CDMs generated on physio-gels could also restrict the invasive behavior of 
tumorigenic KRAS cells [41]. For this, we cultured pre-made KRAS cell spheroids, for 24 hours, onto 
CDMs produced on physio- vs. patho-gels and measured the area covered by invasive KRAS cells 
spreading. In line with our hypothesis, we observed that areas of invasive spreading decreased by ~2 fold 
when the spheroids were cultured on CDMs produced on physio-gels, compared to areas of cells 
spreading into CDMs that were produced onto patho-gels (Figure 4B). As controls, the same spheroids 
were cultured using all assorted matrices and 2D substrates. As seen in Supplemental Figure 4B, control 
fibroblastic-derived ECMs played a restrictive role in all cases; restricting area spreads similarly to 
invasive spreads attained by KRAS cells cultured in CDMs produced onto physio-gels. These data 
suggest the possibility that ECMs produced by control “normal” fibroblasts are inherently restrictive 
regardless of the substrate used to produce them. Importantly, similar results to the ones obtained with 
KRAS cells were also seen using an additional and well-known PDAC cell line, Panc1 (Supplemental 
Figure 4C). Taken together, our data suggest that biomechanical manipulations of CDMs, which restore a 
physiological stiffness-induced isotropic CDM organization/topology, can effectively restrain 
tumorigenic cell growth and invasion to levels like the ones observed when naturally restrictive ECMs 
were used. 
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Figure 4: CDMs generated on physiological substrates restrict tumorigenic cell behaviors by excluding pERK1/2 from the 
tumor cell nucleus. KRAS-driven human pancreatic tumorigenic/invasive cells [41] were cultured in CDMs produced onto 
physio- vs. patho-gels. (A) Graph depicts measured percentages of nuclear Ki67 positive cells, showing median ± interquartile 
ranges. (B) Epifluorescence microscopy images, depleted of the original time 0 spheroid core, showing area spread of RFP 
expressing tumor cell spheroids at 24 hrs. (B-Graph) area spreads corresponding to 95 percent of RFP-spheroid measured 
intensities. The y-axis depicts relative area spread, which was calculated by dividing the final area spread by the area measured 
at time 0 hr.  (C) Indirect immunofluorescence depicting monochromatic images of nuclear pixels (selected using the nuclear 
channel) of pERK1/2 staining, generated using SMIA-CUKIE 2.1.0. https://github.com/cukie/SMIA. Inserts include merged image 
of pERK1/2 (green) and nuclei (blue) channels. (C-Graph) SMIA-CUKIE 2.1.0. https://github.com/cukie/SMIA generated pERK1/2 
nuclear localization intensity levels divided by cytosol localized pERK1/2 levels. Asterisks denote significances of:  ** p<0.01, *** 
p<0.005 and **** p<0.001 compared to nuclei:cytosol ratios obtained when using CDMs produced on patho-gels.  Please refer 
to Supplemental Table for additional data. 
Nuclear accumulation of phosphorylated ERK1/2 (pERK1/2) is regarded as a surrogate 
downstream to constitutive KRAS signaling. Recent studies indicate that ERK2, rather than ERK1, is 
predominantly associated with the regulation of tumor cell invasion in 3D [43-48]. Hence, we next 
questioned the ability of CDMs produced onto physio- vs. patho-gels to maintain high pERK1/2 levels in 
general and, in particular, high nuclear pERK1/2. Western blotting revealed no difference in pERK1/2 
levels in KRAS cells cultured on CDM produced on either physio- or patho-gels, yet there was a modest 
increase in pERK1/2 levels when KRAS-cells were cultured on CDM produced on glass (supplemental 
Figure 5A). Importantly, compared to CDMs produced on patho-gels, the nuclear localization of 
pERK1/2 was modestly, yet significantly (p=0.0003), reduced (from 1.1 to 0.9; by 18 %) in cells cultured 
on CDMs produced on physio-gels (Figure 4C). ECM controls, testing all experimental matrices and bare 
gels, showed a similar trend (supplemental Figure 5B-C and supplemental Table). This data suggests that 
in tumorigenic/invasive cells, nuclear localization of pERK1/2 is controlled via alterations in the CDM 
that, in turn, are affected by fine-tuning the underlying substrate stiffnesses. To elucidate the role of the 
two forms of ERK, we compared the effects of U0126, an inhibitor that indirectly blocks both ERK1 and 
ERK2, to the effects obtained by specifically knocking down ERK1 vs. ERK2 expression (Figure 5). As 
seen in Figure 5A, U0126 reduced CDM-induced invasion/spreading of tumorigenic KRAS cells by 
~40%, compared to the invasion/spreading measured using vehicle control. To transiently knock down 
either ERK1 and/or ERK2, we used specific siRNAs and, as controls, equal amounts of a scrambled (e.g., 
non-specific) siRNA. As seen in Figure 5B, knocking down ERK2, but not ERK1, decreased anisotropic 
CDM-induced invasion by ~60%. Interestingly, invasion of human KRAS cells on CDMs produced on 
Malik et al:     “Substrate softening normalizes stromal matrices” 
 14 
patho-gels under ERK1/2 or ERK2 blockage was similar to the invasion observed on both restrictive 
CDMs produced on physio-gels and by all the control fibroblast-derived ECMs (compare results in 
Figures 4, 5 and supplemental Figure 4). To assure that the CDM-induced effects were indeed ERK2 
dependent, we verified that the level of phosphorylation levels of p90RSK, a downstream target of ERK2, 
was altered in accordance with pERK2, but not pERK1, changes (Figure 5). Taken together, our results 
suggest that ERK2, perhaps via phospho-p90RSK, is essential for matrix-induced invasion of human 
pancreatic tumor cells and that ERK2 blockage reduces anisotropic CDM-induced invasion. 
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Figure 5: CDM-
induced PDAC invasion rates are regulated by tumoral pERK2. (A) Tumor cell spheroids invading through CDMs produced onto 
patho-gels were treated with 20 μM of U0126 to inhibit MEK1/2 upstream to pERK1/2. Invasive area spreads were measured 
(graph) as before as well as in comparison to untreated and vehicle treated (DMSO) controls. Blots depict representative levels 
of pERK1/2 and phospho-p90RSK, downstream to pERK2, in total cell lysates (left) and in nuclear fractions (right). 
Representative measured optical densitometry (O.D.) are provided. (B) Same experiments as in A, but this time tumor cells 
were transfected with lipofectamine (lipo) or scrambled controls as well as siRNAs to ERK1 and/or ERK2 as labeled on 
the figure. Note how effects are seen when ERK2 is downregulated. Significance was calculated in 
comparison to untreated controls and asterisks denote * p<0.05 and *** p<0.005. 
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Lastly but importantly, to further validate both mathematical predictions and the in vitro findings, 
we assessed the nuclear localization pERK1/2 in 8 matching normal (e.g., physiological) and tumor (e.g., 
pathological) human pancreas samples. For this, we used our recently published simultaneous multiplex 
immunofluorescent approach and accompanying software needed for quantitative digital imaging analysis 
[33]. Results, shown in Figure 6A, demonstrated a ~3-fold increase in levels of nuclear localization of 
pERK1/2 in human PDAC samples, compared to nuclear pERK1/2 measured in matching normal/non-
pathological pancreatic epithelial cells.   
Taken together, our results suggest the possibility that the tumorigenic, desmoplastic stroma of 
human pancreatic cancer may be susceptible to modifications resulting in a tumor-restrictive stroma. This 
altered microenvironment might limit the nuclear localization of epithelial pERK1/2, which in turn could 
restrict KRAS-driven PDAC tumorigenicity (Figure 6B). 
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Figure 6:  Human normal stroma maintains pERK1/2 away from nuclei of pancreatic epithelial. (A) Representative examples of 
pancreatic normal (physiological pancreas) and matched pathological PDAC formalin-fixed paraffin-embedded, FFPE, tissue 
samples stained and analyzed using the SMI approach and accompanying SMIA software [33]. Top panels correspond to merged 
images of a representative matching normal and PDAC sample showing epithelium/tumoral cells (red), nuclei (blue), stromal 
cells (grey) and pERK1/2 (green). The monochromatic panels shown below indicate “area masks” generated by the SMIA-CUKIE 
software (SMIA) and depict the levels of pERK1/2 (green) located solely at epithelial or tumoral (red) nuclei areas. Grey masks 
represent stromal areas.  Graph summarizes the measured integrated intensity levels (obtained using SMIA-CUKIE) of nuclear 
tumoral (PDAC; patho) or normal epithelial (normal; physio) localized pERK1/2 levels. P value is indicated.  (B) Summary cartoon 
to highlight that isotropic CDMs, obtained on a physiologically soft substrate, direct pERK1/2 (green) away from nuclear 
locations; restricting KRAS-driven tumorigenic/invasive, akin to PDAC, cell behaviors. 
Discussion  
 Pioneering work by the late Dr. Patricia Keely demonstrated that tumor-associated stromal ECM 
architecture is altered and that stromal ECM anisotropy in vivo serves as a prognostic indicator of poor 
cancer patient outcomes [49]. ECM-imparted physical cues dictate directional migration, as migrating 
cells often use the ECM fibers as attachment points during invasion [42, 50]. Hence, aligned (anisotropic) 
ECM fibers are a characteristic signature for PDAC-associated desmoplasia and indicative of poor patient 
prognosis [4, 5, 51]. Ablation of PDAC-associated desmoplasia was tumor-promoting pre-clinically and 
detrimental to patients in clinical trials [21, 52, 53]. Hence, approaches that can modulate the pro-
tumorigenic aspects of desmoplasia (e.g., desmoplastic ECM anisotropy) to harness the naturally tumor-
restrictive features of a normal microenvironment are highly sought by the field. As such, genetic and 
biomechanical regulation of CAFs seeks to alter their ability to contract and produce an anisotropic ECM. 
For example, increased levels of stromal caveolin-1 in fibroblasts were shown to impact stromal ECM 
anisotropy, via p190RhoGAP activation, which increases intrinsic cell contractile forces and, in turn, 
facilitates in vivo metastatic escape [39]. The presence of syndecan-1 in stroma alters the ECM 
architecture, in vivo and in vitro, and induces the production of an anisotropic ECM that promotes cell 
invasion [54]. Further, overexpression of fibroblast activating protein (FAP) in naive fibroblasts prompts 
the formation of anisotropic ECM, akin to pancreatic CDM, and also induces increased PDAC cell 
invasion [40].  Alternatively, physical approaches have been used to modulate ECM anisotropy, however 
most systems rely on collagen gels or synthetic scaffolds which lack in vivo biochemical complexity. 
Thus, despite reports suggesting that ECM anisotropy is a key regulator of PDAC tumorigenesis [4, 5, 
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51], the particular biomechanical cues that enable production of tumor-restrictive ECM remain mostly 
elusive.  
 Substrate stiffness strongly influences a wide range of cell functions, including some with ECM-
modifying properties, such as cell spreading, survival, proliferation, differentiation, and migration [55]. 
Substrate stiffness also enables ECM remodeling by modulating the expression of genes for ECM 
proteins and ECM-altering enzymes [56]. Fibronectin fibrillogenesis, which is necessary for collagen 
fibrillogenesis in vivo [57], is greatly affected by the underlying substrate stiffness [58]. Fibrillogenesis 
per se is necessary for altering cell-intrinsic forces [59]. Substrate stiffness can also drive collective cell 
migration, which is critical for some types of cancer invasion [60]. Nonetheless, not many studies have 
highlighted the role of substrate stiffness on CAF-derived matrix production, which is one of the most 
important factors believed to influence cancer progression [61]. To correctly interpret the role of 
biomechanical matrix properties that affect cell behavior, it is important to select a system that accurately 
mimics the relevant in vivo physiological and pathophysiological microenvironments. In the present 
study, we adapted our previously described, cell-derived ECM system [34, 62] to identify means to alter 
desmoplastic ECM anisotropy and the role that anisotropic ECMs could play in dictating pancreatic 
cancer tumorigenic cell behavior, such as  proliferation and/or invasion. The advantage of this well-
characterized system is that it is comprised of natural, cell-derived materials and that it offers an in vivo-
like biochemical complexity [62]. However, one known technical limitation of using CDMs produced on 
glass coverslips is a gradient-like heterogeneity in fiber anisotropy, apparent between the bottom (at the 
glass ECM interphase) and top ECM fiber layers (Movie 1). Remarkably, using the physio and patho-gels 
as shock absorbing/buffering materials not only permitted fine-tuning of the underlying substrate stiffness 
and direct the anisotropy of CDM fibers (Figure 2), but it allowed doing so in a homogenous way 
(Supplemental Figure 2). 
 We developed a mathematical model using the experimentally measured cell aspect ratios (Figure 
1 and Supplemental 1A) to predict the anisotropy levels of matrix fibers being produced at the cell-
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substrate interphase. Substrate stiffness affects cytoskeletal actin organization, which, in turn, regulates 
numerous cellular functions, such as cell spreading and migration [63]. Because of the organization of the 
actin network, cells contract along their long axes and generate aligned ECMs [36]. This effect is 
increasingly pronounced as the cell becomes more elliptical [30, 32]. Interestingly, intermediate stiffness 
(e.g. 7 kPa) is associated with induction of maximum elongation of cell and migration, whereas softer 
stiffness (e.g. 1.5 kPa) is associated with dramatic reduction in cell spreading [64, 65]. This prompted us 
to hypothesize that CAFs cultured on soft substrates may exhibit “normalization” of ECM anisotropy. 
Our published model, also referred to as “constitutive material model” [36], is a continuum model that 
addresses fiber alignment and long-range force transmission (i.e., the ability of cells to “sense” each other 
at long distances within an ECM-like mesh within matrices generated on physiological versus 
pathological environments). The model also captures the nonlinear elastic behavior of matrices in 
response to cellular contraction. Based on our experimental data (Figures 1 and 2) and supported by 
mathematical modeling (Figure 3), we suggest that extrinsic (e.g., substrate stiffness) and intrinsic forces 
(e.g., ECM producing cell’s contraction ability) collectively affect the aspect ratios of CAFs, which in 
turn control CAF-derived ECM anisotropy. Therefore, we propose changing substrate stiffness as novel 
means for manipulating extrinsic cues, which may influence the ability of human PDAC-associated CAFs 
to biomechanically remodel CDMs by altering their key biomechanical properties: anisotropy and 
indentation moduli. Our data (Figures 3 and 4) further demonstrated that tumor restrictive responses, 
particularly loss of invasion, are highly correlated with matrix anisotropy. This study is in line with the 
previous data that ECM anisotropy is a major predictor of tumor responses, particularly invasion [30, 66, 
67].  
 Despite harboring “permanent” KRAS mutations, PDAC cells require stromal cues to effectively 
trigger and maintain constitutive KRAS activity in vivo [13]. High, constitutive epithelial/tumoral levels 
of ERK1/2 activity constitute a surrogate to assess high KRAS activity in PDAC cells [68]. ERK1/2-
regulated epithelial to mesenchymal transition has been linked to poor PDAC survival [69]. Activation of 
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key mechano-transducing molecules such as YAP, which depend on ERK1/2 phosphorylation, is also a 
trademark of PDAC [70]. In this study, we observed sustained high levels of nuclear pERK1/2, as 
opposed to merely increased cytosolic levels, in KRAS-driven tumorigenic/invasive human PDAC cells 
cultured on anisotropic matrices (i.e., CDMs produced onto patho-gels).  Yet, pERK1/2 was effectively 
excluded from the nucleus when the cells were cultured on isotropic matrices (i.e., CDMs produced onto 
physio-gels). Additionally, ERK2, and not ERK1, was responsible for regulating the observed ECM-
induced PDAC cell responses (e.g., invasion in Figure 5). These data are in line with our own early 
studies and studies by others which have highlighted a role for ERK2 in tumorigenic responses to 
extracellular-imparted cues [43-48]. Interestingly, high phosphorylated ERK2 levels have been correlated 
with poor survival [71]. Specific nuclear localization of ERK2 induces epithelial mesenchymal transition 
[70] and contributes to drug resistance [72]. Our data suggest that pERK2, possibly regulated by its 
canonical effector p90RSK, is implicated in ECM-induced oncogenic KRAS-driven PDAC invasion 
(Figure 5). This observation agrees with reports showing synthetic lethality between ERK1/2 inhibition 
and p90RSK or its downstream effector CDC25C [73]. It has been reported that integrin activity is 
needed for ERK1/2 nuclear translocation [74]. Future work will focus on assessing if, by remodeling the 
CDM architecture, we also alter integrin signaling. 
 Lastly, this study demonstrated that human PDAC tissues present with enriched tumoral nuclear 
pERK1/2 while normal human tissues exhibit lower levels of nuclear pERK1/2 in the pancreatic 
epithelium (Figure 6). While increased overall levels of pERK1/2 have been reported in human PDAC 
[75], only few studies have looked at epithelial/tumoral nuclear pERK1/2 localization [76].  Therefore, 
these findings may have important implications regarding the therapeutic use of drugs that could exclude 
pERK1/2 from tumoral nuclei. Future efforts will be directed towards further evaluating mechanisms on 
how ERK2, enabled via anisotropic CDMs, may control pERK1/2 translocalization to PDAC nuclei. 
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Conclusions: 
In this study, we have demonstrated that CAFs can be enticed to generate pancreatic cancer-
restrictive CDMs, provided the underlying substrate rigidity matches that of a physiological pancreas. We 
propose that the in vitro measured results can be modeled mathematically, informed by the substrate 
stiffness’ extrinsic forces combined with CAFs’ intrinsic contractility, which jointly directs a biphasic 
matrix fiber anisotropy by maintenance of a low free energy. We found that CDMs generated by CAFs 
onto physiologically soft gels are tumor-restrictive and limit Ki67 incorporation, indicative of reduced 
rates of proliferation and invasion of oncogenic KRAS driven pancreatic cancer cells. Our results also 
suggest that loss of nuclear pERK1/2 in cells cultured on isotropic CDMs is probably regulated by 
restricting ERK2 activity. The observed in vitro results correlated with in vivo measured epithelial nuclear 
pERK1/2 levels, supporting the validity of our tunable pathophysiological 3D CDM system. Hence, the 
therapeutic reprogramming of stromal ECM and/or targeting tumoral ERK2 may provide future means to 
contain PDAC, and possibly other KRAS-driven neoplasias. 
Material and Methods 
Contact for Reagent and Resource Sharing 
All information (manufacturer/source) regarding the chemical and biological reagents has been compiled 
in the Reagents Table. Further information and requests for resources and reagents should be directed to 
and will be fulfilled by the Lead Contacts, Drs. Edna Cukierman (Edna.Cukierman@fccc.edu) and Peter 
I. Lelkes (pilelkes@temple.edu). 
Experimental Model and Subject Details 
Cell Lines 
Human pancreatic CAFs were isolated using an Institutional Review Board approved protocol. Cells were 
characterized, immortalized and authenticated as previously described [77, 78]. Since cultured NIH-3T3 
fibroblasts (from ATCC, CRL-1658™) do not undergo spontaneous myofibroblastic activation [35], these 
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cells were used as inactive fibroblastic cell controls as before [38]. All cells were maintained in a 
humidified incubator at 37oC and 5% CO2.  Control fibroblasts and CAFs were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM; from Mediatech (Manassas, VA) supplemented with 10% FBS, 100 
U/mL Penicillin, 100 mg/mL Streptomycin and 2 mM L-Glutamine. Isogenic pancreatic ductal epithelial 
cells, hTERT and KRAS (hTERT/E6/E7/KRAS; CRL-4038™ [41]) were from ATCC and cultured in 
growth medium containing four parts of low glucose DMEM and one part M3 supplemented with 5% 
FBS containing 100 U/mL Penicillin and 100 mg/mL Streptomycin. 
Method Details 
Preparation of Polyacrylamide gels 
Circular glass coverslips, 18 mm in diameter (Carolina Biological Supply Company; Burlington, NC), 
were activated using 3-Aminopropyl triethoxysilane (APTES) for 10 minutes and washed extensively 
with distilled water followed by treatment with 0.5% glutaraldehyde for 1 hr. To prepare the gel solutions, 
acrylamide and N,N′-Methylenebisacrylamide solution were mixed together in distilled water in the 
desired ratios to generate gel precursor solutions for predicted Young’s moduli of ~1.5 (physio-gels) and 
~7.5 kPa (patho-gels) [79]. The final percentage of gel solutions for a ~1.5 kPa gels was 3% acrylamide 
and 0.15% bisacrylamide and 10% acrylamide and 0.1% bisacrylamide for a ~ 7.5 kPa gel. Gel stiffness 
were validated using atomic force microscopy. Gel polymerization was initiated by addition of 
crosslinkers 10% w/v APS and N,N,N′,N′-Tetramethylethylenediamine accelerator (TEMED) at dilution 
1:000 and 1:10,000 respectively from their stock solutions.  After gentle mixing, 120 μl of the gel solution 
were pipetted onto the activated coverslips and a dichlorodimethylsilane -treated coverslip was carefully 
placed on top of the gel solution. Gels were allowed to polymerize at room temperature for ~10-15 min. 
The top glutaraldehyde and dichlorodimethylsilane (DCDMS)-treated coverslip was gently lifted and gels 
were washed with Milli-Q water and sterilized under a UV lamp ( 365 nm) for 15 min. Covalent 
conjugation of gels with 50 μg/ml collagen-I was performed in 50 mM HEPES buffer, 8.5 pH. Collagen-I 
was crosslinked to the gels using Sulfo-SANPAH for 15 min under the UV lamp, as above. Collagen-
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coated gels were washed extensively with PBS and stored in PBS at 4oC for up to two weeks. The 
Collagen-conjugated gels were equilibrated for 30 min with culture media at 37oC prior to seeding with 
the various fibroblasts. 
Preparation of CDMs onto polyacrylamide gels 
Glass cover slips containing gels coated with collagen were placed inside wells of a 24 well cell culture 
plate (gel side up). Pyrex® cloning cylinders (Sigma Aldrich, St. Louis, MO), 8 mm (height) x 8 mm 
(diameter), were carefully placed at the center of gels and 100 µl culture medium containing 4x104 CAFs 
(or control fibroblasts) was carefully pipetted inside the cylinders. Cylinders were removed after ~1 hr. to 
allow the cells to attach. Next, the cells were covered with 1 ml of fibroblast culture medium, listed 
above, supplemented with 50 μg/ml ascorbic acid. A similar procedure, omitting the use of cloning 
cylinders, was employed for producing CDMs by seeding the cells (CAFs and normal controls) directly 
on collagen coated glass coverslips, as previously published [77].  Fort his, 1.25x105 cells per 12 mm 
coverslips were plated. In both cases, media including freshly weighted and diluted ascorbic acid (50 
μg/ml) was added every day except on the last day (e.g., before extraction).  
Following matrix production (3 days for CDMs on gels or 8 days for CDMs on glass), decellularized 
matrices were obtained using an alkaline detergent (0.5% Triton X-100 and 20 mM NH4OH in PBS), 
followed by DNase I (50 U per mL) treatment [77]. The resulting decellularized matrices were washed 
three times with PBS and stored at 4oC for up to 2 months. All decellularized matrix batches, of control 
fibroblast ECMs and CAF CDMs, underwent rigorous quality control as published [77]. 
Indirect immunofluorescence and image analysis 
Indirect immunofluorescence was as previously described [77]. Briefly, samples were 
fixed/permeabilized, for 3 minutes, with 4% (w/v) paraformaldehyde (EM-grade from Electron 
Microscopy Sciences), 0.5 % (v/v) Triton X-100, and 50 mg/ml sucrose in Dulbecco’s phosphate-
buffered saline and continued fixing, in the absence of triton, for 20 minutes. Samples were blocked for 2 
hr. with Odyssey blocking buffer (TBS) (LI-COR Biotechnology, NE, Cat. 927-50100). For matrix 
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assessments, samples were incubated, for 1 hr., with a rabbit anti-mouse fibronectin antibody (25 μg/ml, 
Abcam, UK Catalog no: ab2413). After incubation with primary antibody, the matrices were washed 
three times, for 10 min. each, with tris buffer saline containing 0.5 % v/v Tween 20 (TBS-T buffer) and 
incubated at room temperature for 45 min with donkey anti-rabbit Cy5 conjugated secondary antibody (15 
μg/ml, Jackson ImmunoResearch, PA Catalog no: 711-175-152). Samples were washed with TBS-T, 
three times. Nuclei were stained with SYBR green (1:50,000 dilution, Thermo Fisher Scientific, 
Waltham, MA) and samples were mounted as previously detailed [77].  Images were captured using a 
spinning disk confocal microscope (Ultraview, Perkin-Elmer Life Sciences, Boston, MA) equipped with a 
60X (1.45 PlanApo TIRF) oil immersion objective. For each condition, three independent experiments 
were conducted and a minimum of 7 images per sample were obtained.  
CDM (or control ECM) alignment measurements were conducted using ImageJ OrientationJ plug 
analyses as published [77, 78]. Isotropic CDMs were identified as matrices containing < 55% alignment, 
while anisotropy was identified as > 55% of fibers distributed at 15 degrees from the mode angle [77, 78]. 
For ERK1/2 subcellular localization quantification, KRAS transformed/invasive [41] cells were 
incubated with rabbit anti-human phospho- p44/42 ERK1/2 (Thr202/Tyr204) (Cell Signaling Technology, 
Danvers, MA, Cat no. 4370,) followed by Cy5-coupled secondary antibody and SYBR green, as above. 
Subcellular localization of p-ERK1/2 (cytosolic vs. nuclear) was quantified using our publically available 
software, SMIA-CUKIE 2.1.0 https://github.com/cukie/SMIA [78]. Images corresponding to the same 
experimental conditions and the same staining procedures were processed identically; 16 to 8 bit level 
conversions were conducted using identical parameters. To find suitable thresholds, to inform the SMIA-
CUKIE software, and distinguish between signal and noise, we applied intensity histogram distributions 
obtained from Photoshop. Selected threshold values (between 1 and 254) for each staining (pERK1/2 or 
nuclei) were consistently used through the study. Images were sorted into experimental folder batches, 
using the “make a batch” software in https://github.com/cukie/SMIA, to include monochromatic matching 
images of nuclei and pERK1/2 per simultaneously acquired images, which served as inputs for the SMIA-
CUKIE 2.1.0 software. Mean intensity levels of pERK1/2 in nuclei vs. cytoplasmic fractions were 
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measured and outputs were plotted as nuclei:cytoplasmic ratios. Show in the figures are representative 
monochromatic image outputs, displaying positive pixels indicative of “nuclear” only pERK1/2 levels, 
accompanied by total pERK1/2 nuclei color overlays.  
Atomic force microscopy (AFM) 
The stiffnesses of the various (gel and cell-derived matrices) substrates were assessed by AFM-
nanoindentation, carried out on a Dimension Icon AFM (BrukerNano, Santa Barbara, CA), using a 
custom-made microspherical tip. The colloidal probe used was generated by attaching a 5 µm-radius 
polystyrene microsphere (PolySciences, Warrington, PA) to the end of a tipples cantilever (Arrow-
TL1Au, NanoAndMore USA, Watsonville, CA) using M-bond 610 epoxy (Structure Probe Inc., West 
Chester, PA). All tests were conducted using filtered 1× PBS to simulate a physiological fluid 
environment. The probe tip was programmed to indent into the sample at a constant z-piezo displacement 
rate of 5 µm/s, up to a maximum indentation depth ~ 1 µm. All CDMs (and control ECMs) used for this 
study were at least 8 μm thick, i.e. exceeding the minimum thickness of 7 µm required for CDM quality 
control [77]. Each sample was tested at a minimum of 10 randomly selected locations to ensure 
consistency and/or to account for spatial heterogeneity. The indentation modulus Eind was calculated by 
fitting the loading portion of each indentation force-depth curve to the Hertz model, 
            (1) 
where F is the indentation force, D is the indentation depth, ν is the poison’s ratio (0.49 for highly swollen 
hydrogels) (57), and Rtip is the radius of the probe tip (≈ 5µm). Since the thickness of the gels (>200µm) 
is more than 2 orders of magnitude greater than the maximum indentation depth, the substrate constraint 
effect was minimal, and thus, finite thickness correction was not needed. The comparison between CDMs 
and adjacent bare gels was done by probing regions with or without the ECM on the same gel for 
consistency. This was possible because CDMs were constrained to the cloning cylinder areas, with the 
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adjacent bare gel areas serving as internal controls. The mechanical properties of the latter were 
indistinguishable from those of intact bare gels that had never been coated with CDMs. 
Mathematical model for predicting cell shape 
Cells change their shapes in accordance with the physicochemical properties of the underlying substrate 
[80]. To mathematically understand how substrate stiffness influences cell morphology, we consider a 
cell cultured on a 2D substrate. We use an energy criterion to determine the cell shape, i.e. we 
hypothesized that a cell adjusts its shape in order to minimize the total free energy of the cell-substrate 
system. The total free energy can be written as, 
𝐸𝐸 = 𝐸𝐸𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 + 𝐸𝐸𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 + 𝐸𝐸𝑖𝑖𝑖𝑖𝑠𝑠            (2)                          
where 𝐸𝐸𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 is the cell energy, 𝐸𝐸𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 is the elastic energy of the underlying substrate and 𝐸𝐸𝑖𝑖𝑖𝑖𝑠𝑠 is the 
interface energy (including the basolateral cell-substrate interface and the apical free cell surface). The 
cell energy is a function of the elastic energy (accounting for cell deformation) and the motor density 
(accounting for contractility). Based on the model for contractile cells [32], 𝐸𝐸𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 can be written as, 
𝐸𝐸𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = ∫ 𝑈𝑈𝐶𝐶(𝜀𝜀𝑖𝑖𝑖𝑖𝐶𝐶 ,𝜌𝜌𝑖𝑖𝑖𝑖)𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐 𝑑𝑑𝑑𝑑            (3) 
where 𝑈𝑈𝐶𝐶 is the cell energy density, 𝜀𝜀𝑖𝑖𝑖𝑖𝐶𝐶  is the elastic deformation of the cell and 𝜌𝜌𝑖𝑖𝑖𝑖 is the motor density. 
The interface energy consists of the basolateral cell-substrate interface energy and the apical free cell 
surface energy.  
𝐸𝐸𝑖𝑖𝑖𝑖𝑠𝑠 = 𝛾𝛾𝐶𝐶𝐶𝐶𝑆𝑆𝐶𝐶𝐶𝐶 + 𝛾𝛾𝐶𝐶𝑆𝑆𝐶𝐶       (4) 
where 𝛾𝛾𝐶𝐶𝐶𝐶 and 𝛾𝛾𝐶𝐶  are interface/surface energy density for cell-substrate interface and free cell surface 
respectively, 𝑆𝑆𝐶𝐶𝐶𝐶 and 𝑆𝑆𝐶𝐶 are the area for cell-substrate interface and free cell surface respectively.  
We characterized the cell shape by defining the aspect ratio 𝑓𝑓 = 𝑎𝑎/𝑐𝑐, where 𝑎𝑎 stands for length 
and 𝑐𝑐 is the cell breadth. For a given substrate (a fixed stiffness), we computed the total free energy of the 
cell-substrate system for various aspect ratios, and chose the energy-minimized one as the preferred cell 
shape. Next, we varied the substrate stiffness and obtained the hypothetical cell aspect ratio as a function 
of stiffness.  
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Mathematical model for predicting CDM alignment 
In terms of the stress-dependent regulation of cell contractility, the contractile stress of the actin network 
can be written [32] as, 
𝜎𝜎 = 𝜌𝜌 + 𝐾𝐾𝜀𝜀                           (5) 
where 𝜌𝜌 is the density of force-dipoles (representing myosin motors/contractility) in the actin network, 𝜀𝜀 
is the strain of the actin network and 𝐾𝐾 is the effective passive stiffness of the actin network. The 
contractility itself depends on the mechano-chemical coupling through mechano-signaling pathways, such 





𝜀𝜀                 (6) 
where 𝜌𝜌0 is the contractility in the absence of adhesions, 𝛼𝛼 and 𝛽𝛽 denote mechano-chemical coupling 
parameters. Additional details of this model have been described elsewhere [32]. 
Short Interfering RNA (siRNA) Transfections 
Transient transfections were performed on the tumorigenic/invasive KRAS cells [41], using 
Lipofectamine® 2000, following the manufacturer’s instructions (Thermo Fisher Scientific, Waltham, 
MA). Non-targeting SMARTpool and siRNA targeting ERK1 or ERK2, each comprising four distinct 
siRNA species, were from Life Technologies-Dharmacon (Lafayette, CO). Transfections were carried out 
in KRAS cell growth media, without FBS or antibiotics. Cells were trypsinized, plated at a density of 
1x105 per well, in a 6-well plate, and mixed with transfection medium, as per manufacturer’s instructions. 
The plate was placed in the incubator for 5 hrs. Following incubation, media was replaced with regular 
KRAS cell growth media (as above) and cells were cultured for an additional 48 hrs.  For spheroid spread 
experiments, cells were trypsinized 24 hrs. post transfection and used for spheroid formation, followed by 
spheroid spread assay (see below). 
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Western blotting 
Cell lysates were obtained using a cell lysis buffer from Cell Signaling Technology (Catalog no. 9803, 
Danvers, MA) supplemented with PierceTM Phosphatase and Protease Inhibitor Mini Tablets (Cat no. 
88667 and 88665, respectively) from Thermo Fisher Scientific (Waltham, MA). Proteins were resolved 
by 4-20% SDS-PAGE gels (Bio-Rad, Hercules, CA) at 60 V and transferred to PVDF membranes using 
semi-dry transfer (Bio-Rad, Hercules, CA). Protein transfer was carried out at 20 V for 30 minutes. Blots 
were incubated with the following primary antibodies: Rabbit anti-human Phospho- p44/42 ERK1/2 
(Thr202/Tyr204) (Cat no. 4370) and rabbit anti-human total- p44/42 ERK1/2 (Cat no. 9102) from Cell 
Signaling Technology (Danvers, MA). Anti-phospho-p90RSK1 (Ser380) (Cat no. 04-418) and anti-
human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Cat no. MAB374) from Millipore 
(Billerica, MA). Horseradish peroxidase- conjugated, anti-species matched, secondary antibodies were 
from Sigma Aldrich (St. Louis, MO). Protein bands were visualized using the Protein Simple 
FluorChemE System, (San Jose, CA). For biochemical nuclear level assessments of pERK1/2 we used the 
Subcellular Protein Fractionation Kit (Thermo Scientific, Waltham, MA), according to the manufacturer’s 
instructions.  
Cell proliferation assay (Ki67) 
Pancreatic human epithelial cells (benign hTERT immortalized and KRAS-driven tumorigenic/invasive; 
[41]) were plated at a density of 2x104 cells/ml, per sample, and cultured for or 24 hrs. Cells were fixed as 
stated in Indirect immunofluorescence and digital imaging analyses section above, prior to staining 
with anti-Ki67 antibody (Cat no. ab15580, Abcam, Cambridge, UK), using the same protocols as above. 
The fraction of proliferating cells was determined by counting the number of cells stained positive for 
Ki67 divided by total number of nuclei, stained using Hoechst 33342 solution (Calbiochem, Billerica, 
MA). At least 5 images were taken per condition, a minimum of two samples was used for each 
experiment and experiments were performed independently a minimum of three times. Data from all three 
experiments was pooled and plotted. 
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Lentiviral infection of KRAS cells 
Target cells were seeded at ~40% confluence in a 6 well plate and allowed to attach overnight. The next 
day, target cells were infected in the presence of media containing mCherry lentivirus (Plv-CMV-Puro 
vector) and 10 ug/ml polybrene (Santa Cruz). After 24 hrs. media was replaced with complete KRAS 
media and allowed to grow for an additional 48 hours. 72 hrs. after the initial infection, cells were 
screened for the presence of mCherry, using the EVOS microscope system. After confirmation of red 
color, media was replaced with KRAS media containing puromycin (12 ug/mL) and selection of mCherry 
positive cells occurred over the next 7-10 days. The resulting cells that survived selection were then used 
for subsequent experiments.  
Spheroid spreading invasion assay 
Red fluorescence protein (RFP)-expressing tumorigenic/invasive KRAS cells were trypsinized and 
resuspended in spheroid formation media (Irvine Scientific, Santa Ana, CA, Catalog ID: 91130) 
overnight; 30 μl drops containing 2.5x103 cells were carefully placed on a lid of a sterile 100 mm Petri 
dish. The dish was filled with 5 mL media, to avoid condensation or drying, and the lid with the “hanging 
drops” was carefully placed, drops facing down, and incubated overnight. Spheroids were carefully 
removed from the lids and placed, one by one, onto the assorted matrices, gels and glass substrates and 
allowed to adhere, for 2 hrs. Subsequently, the spheroid formation media replaced by regular pancreatic 
cancer growth media. Invasion assays lasted 48 hrs. Areas of cell spreading were visualized in an inverted 
microscope equipped with epifluorescent image acquisition capabilities, using a 10X objective. Data were 
normalized to the initial size of each spheroid, as measured at time 0. When indicated, spheroids were 
treated overnight with 20 μM of the MEK1/2 inhibitor U0126 from Calbiochem or the equivalent volume 
of DMSO, or pre-transfected 24 hrs. prior to spheroid formation with the assorted siRNAs. Images were 
processed using MetaMorph 7.8.1.0 software (Molecular Devices, Downingtown, PA). A minimum of 5 
spheres per condition were analyzed in at least three independent experiments. 
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Quantification and Statistical Analysis 
All experiments included a minimum of duplicate samples and repeated independently at least three 
times. Data was plotted using GraphPad Prism and analyzed using unpaired Student’s t-test analyzing 
unpaired conditions each time. Values are presented as median ± interquartile range or mean ± standard 




REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit anti-mouse fibronectin antibody Abcam Cat # ab2413, 
RRID:AB_2262874 









Cat # 4370, 
RRID:AB_2315112 
Rabbit anti-human total- p44/42 ERK1/2  Cell Signaling 
Technology 
Cat # 9102, 
RRID:AB_330744 
Anti-phospho-p90RSK1 (Ser380) antibody Millipore Cat # 04-418, 
RRID:AB_673094 
Anti-Ki67 antibody Abcam Cat # ab15580, 
RRID:AB_443209 
Anti-GAPDH antibody Millipore Cat # MAB374, 
RRID:AB_2107445 
Biological Samples   
Rat Tail Collagen-I Thermo Fisher 
Scientific 
Cat # A1048301 
Surgical samples of patient harvest pancreatic tissue 
(normal and cancer tissue) 




Chemicals, Peptides, and Recombinant Proteins 
U0126  Calbiochem Cat # 662005 
Sulfo-SANPAH Thermo Fisher 
Scientific  
Cat # 22589 
APTES Sigma-Aldrich Cat # A3648 
Glutaraldehyde Sigma-Aldrich Cat # G6257 
Acrylamide Sigma-Aldrich Cat # A4058 
N,N′-Methylenebisacrylamide solution Sigma-Aldrich Cat # M1533 
TEMED Sigma-Aldrich CAS Number 110-
18-9   
APS Sigma-Aldrich Cat # A3678 
DCDMS Sigma-Aldrich Cat no. 440272 
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Paraformaldehyde Electron Microscopy 
Sciences 
CAS #30525-89-4 
Odyssey blocking buffer (TBS) LI-COR Biotechnology Cat # 927-50100 
SYBR green Thermo Fisher 
Scientific 
Cat # S7563 
Lipofectamine® 2000 Thermo Fisher 
Scientific 
Cat # 11668027 
Cell lysis buffer Cell Signaling 
Technology 
Cat # 9803 
PierceTM Phosphatase Thermo Fisher 
Scientific 
Cat # 88667 
Protease Inhibitor Mini Tablets Thermo Fisher 
Scientific 
Cat # 88665 
Spheroid formation media Irvine Scientific Cat # 91130 
Polybrene Santa Cruz Cat # sc-134220 
Critical Commercial Assays 
Subcellular Protein Fractionation Kit Thermo Scientific Cat # 78840 
Experimental Models: Cell Lines 
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Supplementary Figures 
Supplementary Figure. 1:  Changes in 
substrate stiffness dictate a biphasic 
tendency of cell aspect ratio distribution 
in control fibroblast and corresponding 
ECM alignments dictated by 
underlying surface stiffness. (A) 
Changes in substrate stiffness dictate a 
biphasic distribution of control fibroblast 
cell aspect ratios. Epi-fluorescent 
microscopy images depicting cell shape 
(CalceinAM; green) and nuclei (blue) of 
control fibroblasts cultured onto physio 
(~1.5 kPa), patho (~7 kPa) PA gels or 
glass coverslip. Graph (below) includes 
control aspect ratios (length/breadth) as 
calculated using MetaMorph software. 
Data is presented as median ± interquartile 
range. (B) (top) Reconstituted maximum 
projections corresponding to acquired 
confocal images of ECMs produced by 
control fibroblasts cultured onto physio- 
and patho-gels vs glass coverslips. 
Staining of fibronectin (green) and nuclei 
(blue) as well as monochromatic images 
are shown. Colors in bottom panel inserts 
depict angle distributions of ECMs, 
obtained using ‘OrientationJ’ plugin of 
Image-J software.  Insert images were 
normalized using hue values for 
common/mode, cyan, and angle 
visualization as indicated by the gradient 
color bar on the right.  Graph (below) 
shows percentages of fibers distributed at 
15˚angles from the mode for the indicated 
experimental conditions. Note that the 
ECM fiber anisotropy is at peak levels 
when the matrix is produced on patho-gels.  (C) Mathematical model rendition informed using the 
measured median aspect ratios of A, which were used to explain the observed biphasic distribution in 
ECM alignments, showing ratios of % angle distributions at 15 degrees from mode alignment, at the 
cell/matrix interphase.   
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Supplementary Figure 2: 
Patho and Physio-gels direct 
homogenous CDM 
production. Reconstituted 
confocal microscopy images 
obtained from CDMs, produced 
by two independent CAF cells 
isolated from two different 
patients; A cells used through 
the rest of the study to generate 
CDMs and B additional PDAC 
patient-derived CAFs (CDM’). 
CAFs were plated onto the 
assorted substrates: 3-5 days on 
gels and 7-8 on glass coverslip.  
Staining of fibronectin (green) 
and nuclei (blue) and individual 
monochromatic images are 
shown (top row). Inserts 
represent only the bottom layers. 
Middle row includes the same 
CDM images in monochromatic 
depictions, omitting the nuclei 
channel. Colors in bottom 
panels depict angle distributions 
of CDMs, obtained using 
‘OrientationJ’ plugin of Image-J 
software in which HUE was 
used to normalize colors to 
include, cyan, as the mode fibers 
for fiber angle distribution 
visualization, as indicated by the 
gradient color bar on the right. 
Graphs indicate percentage of 
CDM fibers oriented at 15 
degrees from the mode 
measured angle.  Asterisks 
denote: * p<0.05 and **** 
p<0.001. 
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Supplementary Figure 3: 
Indentation moduli of CDMs, but 
not control fibroblast produced 
ECMs, are linearly informed by the 
stiffness of their underlying 
substrates. Indentation moduli of 
decellularized ECMs, produced by 
control fibroblasts or CAF-CDMs 
cultured onto the indicated 
substrates. Accompanying p-value 
table indicates the statistics 
obtained during indentation moduli 
measurements of decellularized 
CDMs generated by control 
fibroblasts or CAFs onto the assorted 
substrates using bare gels (physio 
and patho) as controls.   
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Supplementary Figure 4: 
Tumor cell responses to 3D 
ECMs are restricted by 
isotropic CDMs. (A) 
Syngeneic human pancreatic 
epithelial (benign) and 
KRAS-driven 
tumorigenic/invasive cancer 
cells were cultured within 
assorted fibroblaststic control 
ECM and CAF-CDMs or 
onto 2D substrates for 24 hrs. 
Ki67 levels were measured 
via indirect 
immunofluorescence using 
nuclei stain counts for 
normalization purposes and 
results (median ± 
interquartile range) were 
plotted. (B) RFP expressing 
tumorigenic/invasive cell 
spheroids, of even sizes, were 
allowed to spread on assorted 
control ECM and CAF-
CDMs for 24 hrs. Images 
were acquired at times 0 and 
24 hrs., and 95 percentile 
fluorescence intensities were 
used to measure relative (0 to 
24) area spreads. 
Representative experimental 
images indicating the relative 
masked areas that were used 
to measure cell spread, which 
were plotted on the bottom 
graph, are shown. Asterisks 
denote: * p<0.05, ** p<0.01, 
*** p<0.005 and **** 
p<0.001.  (C) Representative images of Ki67 incorporation (left; red) and nuclei (blue) as well as 
spheroid invasive spread (right) cultured in assorted CDMs as before, but this time with Panc1 PDAC 
cells. 
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Supplementary Figure 5: 
Distributions as opposed to 
levels of pERK1/2 are directed 
by CDMs. (A) Western blot 
depicting the levels of pERK1/2 in 
cell lysates of KRAS-driven 
tumorigenic cultured on top of 2D 
assorted substrates. (B) Indirect 
immunofluorescence microscopy 
images of KRAS-driven 
tumorigenic cells cultured within 
the assorted ECMs. 
Monochromatic image of nuclear 
pERK1/2. Insert, on bottom left, 
shows how cells were double 
stained for total pERK1/2 (green) 
and nuclei (blue; used to select 
nuclei areas). Graph below depicts 
significant loss of nuclear 
pERK1/2 in both control-ECMs 
and CDM-ECMs that were 
generated on physio-gels (C). 
Indirect immunofluorescence and 
graph as in B, but cells were 
cultured onto 2D assorted 
substrates.  Significance is shown 
with regards to corresponding 
physio-gel conditions. 
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Supplemental Table 
 MATRIX PROPERTIES physio patho fold change significance 
gel stiffness (kPa) 1.5 7.5 5 **** 
CDM stiffness (kPa) 0.5 1.1 ~2 * 
CDM alignment (% of 
fibers 15° from mode°) 35 60 ~2 **** 
 





     (%) 
inhibition significance 
proliferation (%) 45 71 37 **** 
migration 
(relative area spread) 0.2 0.40 50 ** 
pERK1/2 localization 
(nuclear/cytoplasmic ratio) 0.90 1.1 18 *** 
 
Matrix properties included bare gels and CDMs made onto these and measuring stiffness, using atomic 
force microscopy as depicted in main text.  Further, Matrix properties also included CDM fiber alignment 
measured by calculating the percentage of fibers aligned at 15 degrees from the mode angle.  Fold 
changes were calculated dividing patho over physio gels or ECMs. 
Matrix induced cell responses included Ki67 incorporation shown as percentage proliferation, spheroid 
spread areas shown as area spreads relative to spheroid core increases and portions of pERK1/2 nuclear 
over cytoplasmic intensity ratios.  Percentage inhibition was calculated as proportion changes attained 
from CDMs made on pathological-gels compared to levels obtained imparted by CDMs produced on 




Movie: CDMs produced onto glass coverslips showing alpha-smooth muscle actin, nuclei and CDM 
fibers. The movie shows each color in monochromatic mode plus overlay and plays a 0.5 micron slice per 
frame going from top to bottom. Note the differences in phenotypes observed at the beginning (top CDM 
layers) vs. end (interphase between bottom CDM production layer and the glass surface) of the movie. 
https://drive.google.com/open?id=1DCPVw_sLPZ0dHpZ4rH7rBH8YQxRxMVJ_ 
 
